Last reviewed · How we verify
NCT07194954
Dietary Fiber and Probiotics in Advanced Colorectal Cancer
NA trial testing Combined Dietary Fiber and Probiotics. in Colorectal Cancer (MSI-H) in 80 participants. Completed in 1 June 2024.
1 March 2023
Quick facts
| Lead sponsor | The First Hospital of Hebei Medical University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 80 |
| Start date | 1 May 2022 |
| Primary completion | 1 March 2023 |
| Estimated completion | 1 June 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Combined Dietary Fiber and Probiotics.
- Standard Nutritional Support
Conditions studied
- Colorectal Cancer (MSI-H) — all drugs for Colorectal Cancer (MSI-H) →
- Malnutrition (Calorie) — all drugs for Malnutrition (Calorie) →
Sponsor
The First Hospital of Hebei Medical University
Who can join
Adults 18 to 75, any sex, with Colorectal Cancer (MSI-H) or Malnutrition (Calorie). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This single-center, prospective, randomized controlled trial was conducted to evaluate the efficacy of a 12-week combined dietary fiber and probiotic supplementation on gut microbiota, immune function, nutritional status, and survival outcomes in malnourished patients with advanced colorectal cancer undergoing conventional therapy, compared to standard nutritional support alone.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07194954
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer (MSI-H)
Currently open trials in the same condition.
- NCT07063550 — Microplastics in Paraneoplastic and Intratumoral for Colorectal Cancer · active not recruiting
- NCT07523763 — Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer · Phase 2 · active not recruiting
- NCT05086692 — A Beta-only IL-2 ImmunoTherapY Study · Phase 1, PHASE2 · recruiting
Other The First Hospital of Hebei Medical University trials
Trials by the same sponsor.
- NCT07467603 — ED50 of Remimazolam for Anesthesia Induction in Frail Elderly Patients · NA · completed
- NCT07243444 — Home-Based Versus Center-Based Cardiac Rehabilitation After CABG Surgery · NA · completed
- NCT07047534 — EEG-Triggered rTMS and Group Therapy for Adolescents With Depression and Self-Harm · NA · completed
- NCT07232693 — Telerehabilitation vs. Center-Based Rehab for Psychological Well-being After CABG · NA · completed
- NCT06344390 — Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke · Phase 1, PHASE2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07194954 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Hospital of Hebei Medical University
- Last refreshed: 1 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07194954.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing